You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: RE43728

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent RE43728 protect, and when does it expire?

Patent RE43728 protects PONVORY and is included in one NDA.

This patent has thirty-four patent family members in twenty-five countries.

Summary for Patent: RE43728

Title:	Thiazolidin-4-one derivatives
Abstract:	The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.
Inventor(s):	Binkert; Christoph (Basel, CH), Bolli; Martin (Allschwil, CH), Mathys; Boris (Egerkingen, CH), Mueller; Claus (Weil am Rhien, DE), Scherz; Michael (Ettingen, CH), Nayler; Oliver (Arlesheim, CH)
Assignee:	Actelion Pharmaceuticals Ltd. (Allschwil, CH)
Application Number:	13/194,172
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent RE43728

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-001	Mar 18, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-002	Mar 18, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-003	Mar 18, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-004	Mar 18, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-005	Mar 18, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: RE43728

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/EP03/13072	Nov 21, 2003

PCT Information
PCT Filed	November 16, 2004	PCT Application Number:	PCT/EP2004/012953
PCT Publication Date:	June 16, 2005	PCT Publication Number:	WO2005/054215

International Family Members for US Patent RE43728

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047128	⤷ Sign Up
Austria	483698	⤷ Sign Up
Australia	2004295047	⤷ Sign Up
Brazil	PI0416752	⤷ Sign Up
Canada	2545582	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.